Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf
Abstract
The role of the kidneys in glucose metabolism is known. In particular, the sodium – glucose cotrasnporters are responsible for glucose reabsorption in the proximal renal tubule. Inhibition of these cotransporters has become the therapeutic target of new hypoglycemic drugs. Dapagliflozin is one of these drugs and seems to be effective in reducing glycosylated hemoglobin, while contributing to weight loss, without increasing the risk for hypoglycemia. The drug’s safety profile is good and its clinical use has already began.
Keywords: dapagliflozin, SGLT2 inhibitor, diabetes mellitus